ezetimibe has been researched along with glucagon-like peptide 1 in 3 studies
| Studies (ezetimibe) | Trials (ezetimibe) | Recent Studies (post-2010) (ezetimibe) | Studies (glucagon-like peptide 1) | Trials (glucagon-like peptide 1) | Recent Studies (post-2010) (glucagon-like peptide 1) |
|---|---|---|---|---|---|
| 2,484 | 563 | 1,465 | 9,484 | 1,208 | 6,374 |
| Protein | Taxonomy | ezetimibe (IC50) | glucagon-like peptide 1 (IC50) |
|---|---|---|---|
| Glucagon-like peptide 1 receptor | Homo sapiens (human) | 0.0051 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Howles, PN; Hui, DY; Ji, Y; Kohan, AB; Lai, J; Li, X; Tso, P; Wang, DQ; Yang, L | 1 |
| Choi, JM; Kim, BJ; Kim, L; Kim, SW; Kim, WJ; Lee, WY; Oh, KW; Park, CY; Park, SE; Park, SW; Rhee, EJ; Sohn, JH; Yang, SJ | 1 |
| Chang, E; Choi, JM; Kim, L; Lee, WY; Oh, KW; Park, CY; Park, DI; Park, SE; Park, SW; Rhee, EJ | 1 |
3 other study(ies) available for ezetimibe and glucagon-like peptide 1
| Article | Year |
|---|---|
Effect of ezetimibe on incretin secretion in response to the intestinal absorption of a mixed meal.
Topics: Analysis of Variance; Animals; Azetidines; Cholesterol; Dietary Sucrose; Enteroendocrine Cells; Enzyme-Linked Immunosorbent Assay; Ezetimibe; Food, Formulated; Gastric Inhibitory Polypeptide; Glucagon-Like Peptide 1; Intestinal Absorption; Lymph; Male; Rats; Rats, Sprague-Dawley | 2010 |
Chronic administration of ezetimibe increases active glucagon-like peptide-1 and improves glycemic control and pancreatic beta cell mass in a rat model of type 2 diabetes.
Topics: Animals; Anticholesteremic Agents; Azetidines; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Ezetimibe; Glucagon-Like Peptide 1; Hyperglycemia; Insulin-Secreting Cells; Male; Rats; Rats, Inbred Strains | 2011 |
Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition.
Topics: Animals; Azetidines; Blood Glucose; Blotting, Western; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Ezetimibe; Glucagon-Like Peptide 1; Insulin; Intestinal Mucosa; L Cells; Male; MAP Kinase Signaling System; Mice; Rats; Rats, Sprague-Dawley; Specific Pathogen-Free Organisms | 2015 |